Article
Repurposing Nintedanib for Pathological Cardiac Remodeling and Dysfunction
2020-12-22
Abstract excerpt
<h4>Background</h4> Heart Failure (HF) is the leading cause of death worldwide. Myocardial fibrosis, one of the clinical manifestations implicated in almost every form of heart disease, contributes significantly to HF development. However, there is no approved drug specifically designed to target cardiac fibrosis. Nintedanib (NTB) is an FDA approved tyrosine kinase inhibitor for idiopathic pulmonary fibrosis (IPF...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- fa4798fb-fa29-5739-a5a3-67ecb3ee92d6
- DOI
- 10.1101/2020.12.21.423817
